Gliomagenesis: genetic alterations and mouse models

Glioblastoma multiforme is the most malignant of the primary brain tumours and is almost always fatal. The treatment strategies for this disease have not changed appreciably for many years and most are based on a limited understanding of the biology of the disease. However, in the past decade, characteristic genetic alterations have been identified in gliomas that might underlie the initiation or progression of the disease. Recent modelling experiments in mice are helping to delineate the molecular aetiology of this disease and are providing systems to identify and test novel and rational therapeutic strategies.

[1]  H. Scherer.  Structural Development in Gliomas , 1938 .

[2]  Richard B. Richter,et al.  Pathology of Tumors of the Nervous System. , 1964 .

[3]  T. Matsui,et al.  FGF modulates the PDGF-driven pathway of oligodendrocyte development , 1990, Neuron.

[4]  F. Tamanoi,et al.  The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae , 1990, Cell.

[5]  O. Bogler,et al.  Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. James,et al.  Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. , 1991, Cancer research.

[7]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[8]  R. Weinberg,et al.  Effects of an Rb mutation in the mouse , 1992, Nature.

[9]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Takahashi,et al.  Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. , 1992, Journal of neurosurgery.

[11]  Margot Mayer,et al.  The inhibition of oligodendrocytic differentiation of O‐2A progenitors caused by basic fibroblast growth factor is overridden by astrocytes , 1993, Glia.

[12]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[13]  D. Louis,et al.  Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis , 1993, Brain pathology.

[14]  K. Kinzler,et al.  Deletion of p16 and p15 genes in brain tumors. , 1994, Cancer research.

[15]  V. P. Collins,et al.  Analysis of glioma cell lines for amplification and overexpression of MDM2 , 1994, Genes, chromosomes & cancer.

[16]  D. Louis.  The p53 Gene and Protein in Human Brain Tumors , 1994, Journal of neuropathology and experimental neurology.

[17]  M. Noble,et al.  Ciliary neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. , 1994, Development.

[18]  R. Hass.  Retrodifferentiation and cell death. , 1994, Critical reviews in oncogenesis.

[19]  S. Finkelstein,et al.  Histological characteristics and expression of acidic and basic fibroblast growth factor genes in intracerebral xenogeneic transplants of human glioma cells. , 1994, Neurosurgery.

[20]  R. Weinberg,et al.  Extensive contribution of Rb‐deficient cells to adult chimeric mice with limited histopathological consequences. , 1994, The EMBO journal.

[21]  J. Cairncross,et al.  p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. , 1994, Journal of the National Cancer Institute.

[22]  L. Donehower,et al.  Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas , 1995, Molecular and cellular biology.

[23]  T. Hunter,et al.  Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signaling , 1995, Cell.

[24]  A. Aguzzi,et al.  Transgenic and gene disruption techniques in the study of neurocarcinogenesis , 1995, Glia.

[25]  A. Guha,et al.  Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop , 1995, International journal of cancer.

[26]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[27]  Y. Yonekawa,et al.  Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. , 1996, Brain pathology.

[28]  V P Collins,et al.  Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. , 1996, Oncogene.

[29]  F. Gage,et al.  Differentiation of the immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of the v-myc oncogene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[31]  G. Thomas,et al.  TOR signalling and control of cell growth. , 1997, Current opinion in cell biology.

[32]  J. Uhm,et al.  Mechanisms of Glioma Invasion: Role of Matrix-Metalloproteinases , 1997, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[33]  A. Pawson,et al.  Proliferation of human malignant astrocytomas is dependent on Ras activation , 1997, Oncogene.

[34]  G. Mills,et al.  MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. , 1997, Cancer research.

[35]  A. Aguzzi,et al.  Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice , 1997, Oncogene.

[36]  D. Haber.  Splicing into Senescence: The Curious Case of p16 and p19ARF , 1997, Cell.

[37]  W Arap,et al.  Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. , 1997, Cancer research.

[38]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[39]  R. McKay,et al.  Regulation of neurogenesis by growth factors and neurotransmitters. , 1998, Journal of neurobiology.

[40]  D. Sidransky,et al.  Role of the p16 tumor suppressor gene in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  R. McKay,et al.  Multiple Routes to Astrocytic Differentiation in the CNS , 1998, The Journal of Neuroscience.

[42]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[43]  R. Jensen,et al.  Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. , 1998, Surgical neurology.

[44]  H. Varmus,et al.  A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. , 1998, Genes & development.

[45]  H. Varmus,et al.  Modeling mutations in the G1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes. , 1998, Genes & development.

[46]  M. Nistér,et al.  Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. , 1998, Cancer research.

[47]  P. Vogt,et al.  Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  B. Barres,et al.  Purification and Characterization of Astrocyte Precursor Cells in the Developing Rat Optic Nerve , 1999, The Journal of Neuroscience.

[49]  S. Altschul,et al.  A public database for gene expression in human cancers. , 1999, Cancer research.

[50]  G. Evan,et al.  Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. , 1999, Molecular cell.

[51]  H. Kashiwazaki,et al.  Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. , 1999, Cancer research.

[52]  D. H. Randle,et al.  Tumor spectrum in ARF-deficient mice. , 1999, Cancer research.

[53]  W. Yung,et al.  Advances in Brief Differential Expression of MMAC / PTEN in Glioblastoma Multiforme : Relationship to Localization and Prognosis 1 , 1999 .

[54]  L. Chin,et al.  Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.

[55]  D. Felsher,et al.  Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.

[56]  T. Jacks,et al.  Insights into cancer from transgenic mouse models , 1999, The Journal of pathology.

[57]  M. Kurrer,et al.  Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. , 1999, The American journal of pathology.

[58]  H. Varmus,et al.  Development of a flexible and specific gene delivery system for production of murine tumor models , 1999, Oncogene.

[59]  M. Rao,et al.  Gliogenesis in the central nervous system , 2000, Glia.

[60]  J. Williams,et al.  Gene therapy strategies for intracranial tumours: glioma and pituitary adenomas. , 2000, Histology and histopathology.

[61]  Webster K. Cavenee,et al.  Pathology and genetics of tumours of the nervous system. , 2000 .

[62]  Karlyne M. Reilly,et al.  Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects , 2000, Nature Genetics.

[63]  Erwin G. Van Meir,et al.  p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma , 2000, Oncogene.

[64]  J. Jorcano,et al.  Opposite Functions for E2F1 and E2F4 in Human Epidermal Keratinocyte Differentiation* , 2000, The Journal of Biological Chemistry.

[65]  F. Gage,et al.  Mammalian neural stem cells. , 2000, Science.

[66]  G. Fuller,et al.  Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. , 2000, The American journal of pathology.

[67]  I. Pollack,et al.  Exploitation of immune mechanisms in the treatment of central nervous system cancer. , 2000, Seminars in pediatric neurology.

[68]  M. Prados,et al.  Biology and treatment of malignant glioma. , 2000, Seminars in oncology.

[69]  Eric C. Holland,et al.  Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice , 2000, Nature Genetics.

[70]  E. Martín-Blanco.  p38 MAPK signalling cascades: ancient roles and new functions , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[71]  J. D. Weber,et al.  The ARF/p53 pathway. , 2000, Current opinion in genetics & development.